Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Human Metabolome Technologies's PEG Ratio or its related term are showing as below:
TSE:6090'
s PEG Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.31
Current: 0.3
During the past 13 years, Human Metabolome Technologies's highest PEG Ratio was 0.31. The lowest was 0.00. And the median was 0.00.
TSE:6090's PEG Ratio is ranked better than 94.59% of 37
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.79
vs TSE:6090: 0.30
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Human Metabolome Technologies (TSE:6090) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Human Metabolome Technologies PEG Ratio Related Terms
Human Metabolome Technologies PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Human Metabolome Technologies's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies PEG Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Human Metabolome Technologies (TSE:6090) has a PEG Ratio of 0.30 as of Aug. 26, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Human Metabolome Technologies and its competitors. According to the industry distribution chart, Human Metabolome Technologies ranks #2 out of 37 companies in the Medical Diagnostics & Research industry, placing it in the top 5.4%.
Is Human Metabolome Technologies' PEG Ratio too high?
Human Metabolome Technologies' current PEG Ratio is 0.30. The Medical Diagnostics & Research industry median PEG Ratio is 1.79. Human Metabolome Technologies' value of 0.30 is 83.2% below this industry median. Based on the distribution chart, Human Metabolome Technologies ranks #2 out of 37 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Human Metabolome Technologies has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' PEG Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #2 out of 37 companies for PEG Ratio. This places Human Metabolome Technologies in the top 5% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.79. Human Metabolome Technologies' value of 0.30 is 83.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Diagnostics & Research company?
The median PEG Ratio among Medical Diagnostics & Research companies is 1.79, based on 37 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Human Metabolome Technologies's current PEG Ratio of 0.30 is 83.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Human Metabolome Technologies and its competitors. For the Medical Diagnostics & Research industry, the median PEG Ratio is 1.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Metabolome Technologies's current PEG Ratio is 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Undervalued. The stock's GF Value™ is 円693.69, compared to a current price of 円625.00 — trading 9.9% below its estimated fair value. The current PEG Ratio is 0.30 and 83.2% below the Medical Diagnostics & Research industry median of 1.79. Human Metabolome Technologies' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current PEG Ratio is 0.30 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued.
The current stock price of 円625.00 is trading 9.9% below its estimated GF Value™ of 円693.69.
GuruFocus considers Human Metabolome Technologies to be Modestly Undervalued.
Key valuation signals for TSE:6090:
PEG Ratio: 0.30
GF Value™: 円693.69 vs. price of 円625.00 (9.9% below fair value)
Industry Position: 83.2% below the Medical Diagnostics & Research median (#2 of 37)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
